Haemonetics Corp
Company Profile
Business description
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Contact
125 Summer Street
BostonMA02110
USAT: +1 781 848-7100
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 March 2026
Employees
3,023
Stocks News & Analysis
stocks
Chart of the Week: Software selloff creates opportunity for these two stocks
stocks
Market is misinterpreting AI impact on cheap ASX share
stocks
AI is a tailwind for beaten down ASX tech share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,409.30 | 26.80 | -0.28% |
| CAC 40 | 8,559.07 | 39.86 | 0.47% |
| DAX 40 | 25,175.94 | 189.69 | 0.76% |
| Dow JONES (US) | 49,482.15 | 307.65 | 0.63% |
| FTSE 100 | 10,806.41 | 125.82 | 1.18% |
| HKSE | 26,765.72 | 175.40 | 0.66% |
| NASDAQ | 23,152.08 | 288.39 | 1.26% |
| Nikkei 225 | 58,583.12 | 1,262.03 | 2.20% |
| NZX 50 Index | 13,610.95 | 85.37 | 0.63% |
| S&P 500 | 6,946.13 | 56.06 | 0.81% |
| S&P/ASX 200 | 9,175.50 | 27.40 | -0.30% |
| SSE Composite Index | 4,147.23 | 29.82 | 0.72% |